Opens in a new tab

Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 22 August 2024)

Date22 August 2024
CourtCFI
DivisionMunich (DE) Central Division - Section
Type of actionApplication RoP262.1 (b)
Case number(s)UPC_CFI_75/2023
Registry referenceApp_588681/2023 · ORD_591107/2023 · UPC_CFI_75/2023
PartiesAstellas v. Helios, Riken, Osaka

Official decision (PDF) · UPC registry entry

Case timeline

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 22 August 2024 (UPC_CFI_75/2023, ACT_464985/2023, ORD_591107/2023), the judge-rapporteur of the Munich Central Division (A. Kupecz) granted the firm Mathys & Squire access to the pleadings and evidence in the revocation action on EP 3 056 563 brought by Astellas Institute for Regenerative Medicine against Healios, Riken and Osaka University, after redaction of personal data and of the confidential passages identified by Astellas. The order confirms that once proceedings have ended in settlement, a general interest is enough to obtain access.

Question

May a third party showing only a general interest obtain access to the pleadings and evidence of proceedings ended by settlement, and may the claimant obtain redaction of sensitive information?

Decision

The judge had awaited the Court of Appeal decision of 10 April 2024 on public access before ruling. As the proceedings ended on 23 July 2024 on the parties’ joint application, the applicant’s general interest suffices and Astellas’s objection that there was no direct interest fails: once the case has ended in settlement, the balance of interests will normally favour access. No abuse, public order ground or third-party interest stands in the way. Astellas’s interest is protected by redaction, justified by the commercial risk and by the fact that the applicant may act for competitors, of information on its product timeline in its reply of 29 November 2023 and in the rejoinder of 29 December 2023 (Rule 262.2 RoP). Personal data is redacted under Regulation (EU) 2016/679. Leave to appeal is granted and access is deferred for 16 days after service.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 10, 45 and 73(2)(b)(ii)
Rules of Procedure
Rules 220.2, 224.1(b) and 262
Regulation (EU) 2016/679
protection of personal data
Case law cited
Ocado Innovation v Autostore, Court of Appeal, 10 April 2024, Ocado Innovation v Autostore, Nordic-Baltic Regional Division, 17 October 2023, The Hague Local Division, 29 July 2024 (UPC_CFI_131/2024)

Related decisions

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Written procedure (UPC), Confidentiality club.

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

  • UPC_CFI_75/2023 official number

Follow this case

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

  1. 21 September 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 21 September 2023) Revocation Action · UPC_CFI_75/2023

    La demande d'accès d'un tiers au mémoire introductif et à la lettre de signification est rejetée : l'éducation et la formation ne sont pas un motif légitime, et la lettre n'est ni une écriture ni une pièce.

  2. 11 October 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_75/2023, 11 October 2023) Revocation Action · UPC_CFI_75/2023

    Le mémoire en défense à l'action en nullité est réputé signifié le 29 septembre 2023, la notification générée par le CMS valant signification au sens de la règle 278.1.

  3. 28 December 2023 Mathys & Squire v Astellas (CFI, 28 December 2023) Application RoP262.1 (b) · UPC_CFI_75/2023

    La demande d'accès de Mathys & Squire est mise en attente jusqu'à la décision de la cour d'appel sur la règle 262.1 b), à produire dans les trois semaines.

  4. 18 March 2024 Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 18 March 2024) Revocation Action · UPC_CFI_75/2023

    Le document D18 est admis sous réserve d'une réponse de la défenderesse avant le 11 avril 2024, la valeur du litige est fixée à 4 000 000 euros et l'audience confirmée au 25 juin 2024.

  5. 22 August 2024 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 22 August 2024) Application RoP262.1 (b) · UPC_CFI_75/2023

What the record states

Nature of the act
Application RoP262.1 (b)
Outcome (Dhenne Avocats summary)
Mathys & Squire obtient l'accès aux écritures et pièces de l'action en nullité close par transaction, après occultation des données personnelles et des informations confidentielles d'Astellas. L'appel est autorisé.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 056 563
Method of producing retinal pigment epithelial cell
recorded proprietor: Healios KK, RIKEN et University of Osaka NUC
Mentioned in the analysis (role not qualified)
Also mentioned in 7 other decision(s): Mathys & Squire v Astellas Institute for Regenerative Medicine (CFI, 4 · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 23 Ju · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 18 M · Mathys & Squire v Astellas (CFI, 28 December 2023) · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_C · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 21 Se · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.